002675 东诚药业
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入647,229-23.90%3,275,6483,582,9553,912,0503,418,978
减:营业总成本597,995-21.81%2,826,4773,034,6453,349,5202,836,583
    其中:营业成本363,781-18.62%1,805,9582,044,3752,309,8761,752,036
               财务费用3,758-81.31%31,2936,15157,99051,628
               资产减值损失32,986--(111,886)(80,290)(217,321)--
公允价值变动收益----(19,474)4011,1711,047
投资收益3,054-143.28%(8,654)(39,614)(13,325)8,722
    其中:对联营企业和合营企业的投资收益----(37,751)(41,716)(19,962)1,326
营业利润84,009-3.10%341,662448,252356,932609,145
利润总额83,989-3.00%337,282445,576356,099611,375
减:所得税费用18,058-23.72%83,06592,74995,24993,902
净利润65,9314.79%254,216352,828260,850517,473
减:非控股权益1,603-87.48%44,48145,536109,28899,707
股东净利润64,32828.38%209,736307,291151,561417,766

市场价值指针
每股收益 (元) *0.07828.29%0.2540.3800.1890.521
每股派息 (元) *----0.1250.1500.1500.250
每股净资产 (元) *6.0734.48%5.7915.759--5.570
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容